{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:21:14Z","timestamp":1760188874786},"reference-count":17,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,12,7]],"date-time":"2005-12-07T00:00:00Z","timestamp":1133913600000},"content-version":"vor","delay-in-days":7494,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[1985,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ten patients with chronic type B hepatitis were treated with three courses of adenine arabinoside monosphosphate (Ara\u2010AMP). The drug was given intramuscularly at a dosage of 10 mg\/kg\/day in ten\u2010day courses during each of three sequential months. The patients were all men, aged 31\u201361 years, who were known to have had chronic hepatitis for one to four years. Each of the ten\u2010day courses of Ara\u2010AMP was accompanied by a marked inhibition in the serum levels of hepatitis B virus (HBV) DNA and DNA polymerase activity. However, HBV\u2010DNA remained detectable in every patient during treatment and invariably rebounded to pretreatment levels soon after each course was stopped. One patient developed severe, and two patients developed mild neuromuscular side effects. During a 12\u201318\u2010month follow\u2010up period, only one of the ten patients has had a sustained clinical, serum biochemical, and serological remission. In this patient, serum HBeAg, HBV\u2010DNA, and DNA polymerase became undetectable three months after the final course of treatment; serum aminotransferase levels subsequently fell into the normal range; and a follow\u2010up liver biopsy showed a diminution in the chronic inflammatory cell activity and a disappearance of intrahepatic hepatitis B core antigen reactivity. Thus, multiple ten\u2010day courses of Ara\u2010AMP do not induce a high rate of remissions in this disease and are associated with appreciable neuromuscular toxicity. Ara\u2010AMP is a potent inhibitor of serum levels of hepatitis B virus, but Ara\u2010AMP therapy has not been shown to have long\u2010term beneficial effects in chronic type B hepatitis.<\/jats:p>","DOI":"10.1002\/jmv.1890150204","type":"journal-article","created":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T12:00:16Z","timestamp":1172836816000},"page":"121-128","source":"Crossref","is-referenced-by-count":22,"title":["Treatment of chronic type B hepatitis with multiple ten\u2010day courses of adenine arabinoside monophosphate"],"prefix":"10.1002","volume":"15","author":[{"given":"Jay H.","family":"Hoofnagle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reginald G.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Chris","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion G.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark I.","family":"Avigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne G.","family":"Waggoner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruby","family":"Howard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Anthony","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen E.","family":"Straus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,12,7]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/0016-5085(81)90075-5","article-title":"A controlled trial of adenine arabinoside in HBsAG\u2010positive chronic liver disease","volume":"80","author":"Bassendine MF","year":"1981","journal-title":"Gastroenterology"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890090109"},{"key":"e_1_2_1_4_2","first-page":"1073","article-title":"Fatal vidarabine toxicity in a patient with normal renal function","volume":"246","author":"Etta LV","year":"1981","journal-title":"Journal of the American Medical Association"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-94-6-744"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(84)90601-2"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840020606"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1128\/jvi.12.5.995-1005.1973","article-title":"DNA polymerase associated with human hepatitis B antigen","volume":"12","author":"Kaplan PN","year":"1973","journal-title":"Journal of Virology"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(83)80114-0"},{"key":"e_1_2_1_10_2","first-page":"537","volume-title":"Viral Hepatitis. 1981 International Symposium","author":"Merigan TC","year":"1982"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.239.16.1648"},{"key":"e_1_2_1_12_2","first-page":"531","volume-title":"Progress in Liver Diseases","author":"Popper H","year":"1976"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/144.4.358"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jama.1979.03290270020010","article-title":"Toxicity of vidarabine","volume":"241","author":"Sacks SL","year":"1979","journal-title":"Journal of the American Medical Association"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/143.6.772"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)90600-0"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.23.9.717"},{"key":"e_1_2_1_18_2","first-page":"659","article-title":"Hepatitis B core and surface antigen in liver tissue: light and electron microscopic localization by the peroxidase labelled antibody method","volume":"36","author":"Yamada G","year":"1977","journal-title":"Laboratory Investigation"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.1890150204","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.1890150204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T23:21:36Z","timestamp":1697757696000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.1890150204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,6]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1985,6]]}},"alternative-id":["10.1002\/jmv.1890150204"],"URL":"https:\/\/doi.org\/10.1002\/jmv.1890150204","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,6]]}}}